['osteoarthritis, knee']
['neo6860', 'placebo']

        Inclusion Criteria:

        Males and females Any ethnic origin Between 18 and 55 years of age Body mass index (BMI)
        between 18.0 and 32.0 kg/m2 inclusive Body weight between 50 kg and 100 kg inclusive
        Subjects must be in good health, as determined by Medical history, Physical examination,
        Vital sign assessment, 12-lead electrocardiogram (ECG), Clinical laboratory evaluations
        (congenital non-haemolytic hyperbilirubinaemia is acceptable) Subjects will have given
        their written informed consent to participate in the study and to abide by the study
        restrictions

        Exclusion Criteria:

        Male subjects who are not willing, or whose partners are not willing, to use appropriate
        contraception (such as a condom with spermicidal foam/gel/film/cream/suppository), or to
        refrain from donating sperm from the time of the first dose until 3 months after the final
        dosing occasion.

        Subjects who have donated blood in the 3 months prior to screening, plasma in the 7 days
        prior to screening or platelets in the 6 weeks prior to screening Subjects who consume more
        than 28 units of alcohol per week if male or consume more than 21 units of alcohol per week
        if female

        Subjects who have used any medication within 7 days of the first dose administration,
        unless in the opinion of the Investigator the medication will not interfere with the study
        procedures or compromise safety:

        Subjects who have a clinically significant pulse rate, blood pressure or temperature that,
        in the opinion of the investigator, increases the risk of participating in the study, in
        accordance with the CRU reference ranges at screening and prior to first dose Subjects with
        a positive urine drug screen (confirmed by repeat) at screening or first admission, or a
        positive alcohol breath test result (confirmed by repeat) at screening or first admission
        Subjects who have an abnormality in the 12-lead ECG that, in the opinion of the
        investigator, increases the risk of participating in the study, in accordance with the CRU
        reference ranges at screening Subjects with, or with a history of, any clinically
        significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychiatric,
        respiratory, metabolic, endocrine, haematological or other major disorders as determined by
        the Investigator ALT or AST >1.5 times ULN at screening and/or prior to first dose,
        confirmed by repeat testing Subjects considered non-acceptable responders to the
        intradermal capsaicin test at screening, defined as maximum VAS score of <3 or 10 Subjects
        who, in the opinion of the Investigator, should not participate in the study
      